



## Fellows Network Newsletter

**Winter 2020/2021**

---

The HTRS Fellows Network is pleased to present our Winter 2020/2021 Newsletter! In this issue, you will find:

- *Announcements, funding opportunities and upcoming meetings - **RSVP today!***
- *Spotlight on HTRS Fellow Member: Valery Li, MD*
- *Connection to CLOT+ to highlight recent high-impact studies*



Follow us: [@HTRSfellows](https://twitter.com/HTRSfellows)

## Announcements

***Please Join Us at ASH 2020:***

***~ RSVP by Wednesday, December 2 ~***

**HTRS/Genentech “Best of ASH”**

# Networking Event

Presented by the HTRS ConECCTOR Network and  
sponsored by



**Monday, December 7, 2020**

**8:00 PM ET / 7:00 PM CT / 6:00 PM MT / 5:00 PM PT**

To RSVP, please [CLICK HERE](#)

---

## **HTRS Virtual Grant Review Workshop**

**Post-ASH: December 11, 2020**

**~ PLEASE APPLY TODAY ~**

HTRS ConECCTOR invites you to participate in our Grant Review Workshop to be held virtually on Friday, December 11, 2020 from 11:00 AM – 12:30 PM ET. This is an unparalleled opportunity!

Accepted applications\* will be discussed in a small-group virtual meeting with the following HTRS-member faculty members:

- **Margaret Ragni, MD, MPH**, *Director, Hemophilia Center of Western PA / Professor of Medicine and Clinical Translational Science, University of Pittsburgh School of Medicine*
- **Courtney Thornburg, MD**, *Professor, Medical Director, Division of Pediatric Hematology/Oncology, Rady Children's Hospital, University of San Diego*

\*For the required application form for grant-specific materials and/or a description of the project and career goals, [CLICK HERE](#) or email [jziegler@versiti.org](mailto:jziegler@versiti.org) as soon as possible.

---

**ASH 2020 Virtual ConECCTOR**

# Meeting: December 8, 2020

~ **Please RSVP TODAY!** ~

Please join our next virtual HTRS ConECCTOR Meeting during ASH on Tuesday, December 8th from 4:30 to 6:00 PM CT. Special thanks to Octapharma, 2020 Sponsor of the HTRS ConECCTOR Network, and Spark Therapeutics, Inc., 2020/2021 Sponsor of the HTRS ConECCTOR Network.

The **AGENDA** features the following HTRS-member faculty:

- **Alice Ma, MD:** "How to Say No"
- **Ayesha Zia, MD:** "How to Build a Research Program: Emphasis on Conducting/Balancing Research During COVID"
- **Angela Weyand, MD:** "Incorporating Social Media Into Your Hematology Practice"

For more details, **[CLICK HERE](#)**

*Special thanks to Octapharma, 2020 Sponsor of the HTRS ConECCTOR Network, and Spark Therapeutics, Inc., 2020/2021 Sponsor of the HTRS ConECCTOR Network.*

---

---

## 2021 HTRS/Novo Nordisk Clinical Fellowship Award (CFA) in Hemophilia and Rare Bleeding Disorders

~ **The Call for Applications is open: Apply by December 15, 2020** ~

Our CFA is focused on hemophilia and rare bleeding disorders for one academic year (July 1, 2021 - June 30, 2022). During the fellowship year, the awardee is mentored by an experienced MD, MD/PhD or DO working in hemophilia or rare bleeding disorders at an established U.S.-based hemostasis treatment center (HTC).

See **[Request for Proposals](#)** for details:

- **All applications must be submitted via HTRS Online Grant Submission site: <https://htrs.smapply.org>**
- **Deadline for 2021 applications: Tuesday, December 15, 2020**

Questions about the program may be directed to Jennifer in the HTRS Office at [htrs@versiti.org](mailto:htrs@versiti.org) or [jziegler@versiti.org](mailto:jziegler@versiti.org).

**HTRS recognizes Novo Nordisk as a Founding Supporter of**

the HTRS/Novo Nordisk CFA Program and a supporter of one (1) 2021 HTRS/Novo Nordisk CFA in Hemophilia and Rare Bleeding Disorders



---

## HTRS Pre-ASH Trainee Workshop:

**For Residents and Fellows who have already applied:  
December 3, 2020**

Virtual Event: “Building a Career in Hemostasis and Thrombosis”

**Watch for application to be announced in January for Pre-HTRS Trainee Workshop to be held in March 2021!**

*The twice-annual **HTRS Trainee Workshop** offers a unique opportunity for 30 MDs or DOs in training who are interested in building careers in hemostasis and/or thrombosis in pediatric or adult medicine.*

For more info on Trainee Workshops, [\*\*CLICK HERE\*\*](#)

*This ongoing educational activity is supported by educational grants from founding supporter Novo Nordisk Inc., CSL Behring, Shire/Takeda, and Grifols.*

---

## 2021 HTRS Student Research Award Program

**~ Now accepting applications: Deadline March 12, 2021 ~**

HTRS is accepting applications for the 2021 HTRS Student Research Awards (SRA), an 8-10 week program aimed at introducing medical, PhD, MD/PhD and PharmD students to the field of hemostasis and thrombosis by supporting the students' work on targeted research projects focused on hemostasis and thrombosis. Proposed projects may be lab-based, clinical or epidemiologic.

The experience includes collaboration with a research mentor, a \$5,000 stipend and a \$2,000 travel allowance to present at a 2021 scientific meeting.

Sponsoring lab/organization receives a \$1,000 stipend.

See [Request for Applications](#).

- To apply, please visit: <https://htrs.smapply.org>
- Deadline for 2021 applications: March 12, 2021

Questions about the program may be directed to Teresa Holzen, PhD, Manager, Grants and Membership in the HTRS Office at [htrs@versiti.org](mailto:htrs@versiti.org) or [tholzen@versiti.org](mailto:tholzen@versiti.org).

---

---

## HTRS Fellow Spotlight

### **Valery Li, MD**

Clinical Fellow,  
University of Washington/Fred Hutchinson  
Cancer Research Center



#### **1. Describe your path to non-malignant hematology.**

During the first two years of medical school, I found myself really enjoying the weekly histology/pathology sessions, particularly the blood smear evaluation. During the last year of medical school, I worked with Dr. Peter Gillette who was the director of the sickle cell program at SUNY Downstate in Brooklyn.

Entering into Internal Medicine residency, I knew I was interested in Hematology/Oncology but it was not until mid-way through my second year that I knew for certain non-malignant hematology was the better fit for me. By happenstance, I had a string of non-malignant hematology patients within the first three months of my intern year - TTP, severe anemia due to babesiosis and

warm autoimmune hemolytic anemia. It was so much fun learning all the different laboratory tests and how they are performed, discussing the differential diagnoses based on labs or bone marrow examinations and subsequent therapies for each. I'll never forget the impressive schistocyte count of that TTP patient or the "Maltese cross" on the blood smear of the patient with a Babesia burden of 8%. As my residency at NYP-Weill Cornell has had a strong legacy of non-malignant hematology program, I was fortunate to have worked with Dr. Andrew Schafer on the consult service, which further solidified my interest.

I then began working with Dr. Gerald Soff, the head of non-malignant hematology at Memorial Sloan Kettering Cancer Center, on various projects involving the use of romiplostim for chemotherapy-induced thrombocytopenia.

## **2. What do you love about non-malignant hematology?**

I really enjoy how accessible and tangible the evidence can be while one is undergoing a hematologic workup, whether it is examining a simple blood smear or a marrow aspirate. Every patient starts out as a mystery case and it is up to us to be the detective and find out what's going on. I also love that as a non-malignant hematologist, we get consulted by every conceivable medical or surgical specialist and subspecialist and thus we are exposed to patients with a plethora of other primary diagnoses. There is never a dull moment when we stay curious about topics that may seemingly have nothing to do with hematology.

## **3. What are you doing now?**

I moved to Seattle after IM residency in 2018 to start my Hematology/Oncology fellowship at University of Washington/Fred Hutchinson Cancer Center. However, I always remembered the advice that Dr. Gillette imparted before I graduated from medical school. He recommended that I spend some time in the blood bank and learn more about all the products that I'll invariably transfuse to my patients. During the first year of my clinical year as a fellow, I did exactly that. I rotated through Bloodworks Northwest, which is the regional blood bank that supports most of the hospitals in the Puget Sound region (western part of Washington state and some parts of Oregon). I enjoyed it so much that I decided to take a year off from my Hematology training to pursue a Transfusion Medicine fellowship at Bloodworks, which I completed in June 2020. I am now back to completing my Hematology fellowship and am currently pursuing platelet research under Dr.

Moritz Stolla's Lab.

#### **4. What advice would you offer trainees interested in non-malignant hematology?**

Mentorship is key. Don't let your oncology counterparts intimidate you! There might be more of them, but our enthusiasm and dedication to the field is no less impressive. I have met many non-malignant hematologists who are passionate about mentoring the next generation of hematologists. If you are interested in the field, I recommend reaching out to your residency leadership or an attending you've worked with previously to inquire about potential mentors. In fact, it was through another attending that I'd previously worked with that I was introduced to my mentor Dr. Soff.

Another tip: always examine the smear yourself!

### **Recent High-Impact Articles from CLOT+**

**We are excited to continue our new collaboration with [CLOT+](#) to provide curated, high-yield hemostasis and thrombosis articles via this newsletter.**

**For more information and to access the links below, click [HERE](#) to register for free at CLOT+.**

[The Use of Therapeutic-Dose Anticoagulation and Its Effect on Mortality in Patients With COVID-19: A Systematic Review.](#)  
[Recurrent thrombosis in patients with antiphospholipid antibodies and an initial venous or arterial thromboembolic event: A systematic review and meta-analysis.](#)

Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620960797. doi: 10.1177/1076029620960797. (*Systematic review*)

[Venous and arterial thromboembolic events with immune checkpoint inhibitors: A systematic review.](#)

Thromb Res. 2020 Dec;196:444-453. doi: 10.1016/j.thromres.2020.09.038.  
Epub 2020 Oct 8. (*Systematic review*)

[Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS.](#)

Eur Heart J. 2020 Oct 1;41(37):3533-3545. doi: 10.1093/eurheartj/ehaa670.  
(*Original study*)

[Efficacy and safety of chemical thromboprophylaxis in renal transplantation - A systematic review.](#)

Thromb Res. 2020 Aug;192:88-95. doi: 10.1016/j.thromres.2020.05.013. Epub  
2020 May 19. (*Systematic review*)

[Evaluation of Sepsis-Induced Coagulopathy in Critically Ill Pediatric Patients with Septic Shock.](#)

Thromb Haemost. 2020 Oct 29. doi: 10.1055/s-0040-1718736. (*Original study*)

[Efficacy and safety of non-vitamin K anticoagulants and warfarin in patients with atrial fibrillation and heart failure: A network meta-analysis.](#)

Thromb Res. 2020 Aug 14;196:109-119. doi: 10.1016/j.thromres.2020.08.021.  
(*Systematic review*)

[The increased risk of bleeding due to drug-drug interactions in patients administered direct oral anticoagulants.](#)

Thromb Res. 2020 Aug 3;195:243-249. doi: 10.1016/j.thromres.2020.07.054.  
(*Original study*)

**Third HTRS Trainee Career Development Webinar  
Coming soon in early 2021!**

---

---

Hemostasis and Thrombosis Research Society

Fellows Network Newsletter

**2020/2021 Fellows Network Council Members:**

*Jennifer Yui, MD, University of Pennsylvania, Chair*

*Anna Parks, MD, University of California, San Francisco, Chair-Elect*

*Sherwin DeSouza, MD, Cleveland Clinic Foundation/Taussig Cancer  
Institute*

*Harry Fuentes Bayne, MD, Mayo Clinic*

*George Goshua, MD, Yale*

*Hana Lim, MD, MS, Weill Cornell Medicine*

8733 Watertown Plank Road

Milwaukee, WI 53266-3548

(414) 937-6569 | [htrs@versiti.org](mailto:htrs@versiti.org) | [htrs.org](http://htrs.org)